Robert W. Baird Forecasts Strong Price Appreciation for Immutep (NASDAQ:IMMP) Stock

Immutep (NASDAQ:IMMP) had its price target boosted by Robert W. Baird from $6.00 to $7.00 in a report issued on Friday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the biotechnology company’s stock.

Immutep Stock Performance

IMMP opened at $1.97 on Friday. The stock’s 50 day moving average price is $2.10 and its two-hundred day moving average price is $2.32. Immutep has a 12-month low of $1.58 and a 12-month high of $3.34. The company has a quick ratio of 18.25, a current ratio of 18.25 and a debt-to-equity ratio of 0.01.

Institutional Trading of Immutep

Institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in shares of Immutep during the second quarter worth $26,000. BNP Paribas Financial Markets raised its position in shares of Immutep by 15.4% during the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 4,700 shares during the period. XY Capital Ltd bought a new position in shares of Immutep during the 2nd quarter valued at about $105,000. Virtu Financial LLC grew its position in shares of Immutep by 269.4% in the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 32,864 shares during the period. Finally, Meridian Wealth Management LLC increased its stake in Immutep by 4.5% during the 3rd quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock worth $881,000 after purchasing an additional 17,250 shares in the last quarter. Institutional investors and hedge funds own 2.32% of the company’s stock.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.